skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease

Authors:
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;  [1]
  1. Lilly
Publication Date:
Research Org.:
Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Sponsoring Org.:
INDUSTRY
OSTI Identifier:
1558306
Resource Type:
Journal Article
Journal Name:
MABS-Austin
Additional Journal Information:
Journal Volume: 11; Journal Issue: (6) ; 2019
Country of Publication:
United States
Language:
ENGLISH

Citation Formats

Benschop, Robert J., Chow, Chi-Kin, Tian, Yu, Nelson, James, Barmettler, Barbra, Atwell, Shane, Clawson, David, Chai, Qing, Jones, Bryan, Fitchett, Jon, Torgerson, Stacy, Ji, Yan, Bina, Holly, Hu, Ningjie, Ghanem, Mahmoud, Manetta, Joseph, Wroblewski, Victor J., Lu, Jirong, and Allan, Barrett W. Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease. United States: N. p., 2019. Web. doi:10.1080/19420862.2019.1624463.
Benschop, Robert J., Chow, Chi-Kin, Tian, Yu, Nelson, James, Barmettler, Barbra, Atwell, Shane, Clawson, David, Chai, Qing, Jones, Bryan, Fitchett, Jon, Torgerson, Stacy, Ji, Yan, Bina, Holly, Hu, Ningjie, Ghanem, Mahmoud, Manetta, Joseph, Wroblewski, Victor J., Lu, Jirong, & Allan, Barrett W. Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease. United States. doi:10.1080/19420862.2019.1624463.
Benschop, Robert J., Chow, Chi-Kin, Tian, Yu, Nelson, James, Barmettler, Barbra, Atwell, Shane, Clawson, David, Chai, Qing, Jones, Bryan, Fitchett, Jon, Torgerson, Stacy, Ji, Yan, Bina, Holly, Hu, Ningjie, Ghanem, Mahmoud, Manetta, Joseph, Wroblewski, Victor J., Lu, Jirong, and Allan, Barrett W. Mon . "Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease". United States. doi:10.1080/19420862.2019.1624463.
@article{osti_1558306,
title = {Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease},
author = {Benschop, Robert J. and Chow, Chi-Kin and Tian, Yu and Nelson, James and Barmettler, Barbra and Atwell, Shane and Clawson, David and Chai, Qing and Jones, Bryan and Fitchett, Jon and Torgerson, Stacy and Ji, Yan and Bina, Holly and Hu, Ningjie and Ghanem, Mahmoud and Manetta, Joseph and Wroblewski, Victor J. and Lu, Jirong and Allan, Barrett W.},
abstractNote = {},
doi = {10.1080/19420862.2019.1624463},
journal = {MABS-Austin},
number = (6) ; 2019,
volume = 11,
place = {United States},
year = {2019},
month = {8}
}

Works referenced in this record:

Bispecific antibody pipeline moves beyond oncology
journal, October 2017


Developmental Toxicity and Fertility Assessment in Rabbits with Tabalumab: A Human IgG4 Monoclonal Antibody: TABALUMAB REPRODUCTIVE ASSESSMENT RABBIT
journal, June 2015

  • Breslin, William J.; Hilbish, Kim G.; Martin, Jennifer A.
  • Birth Defects Research Part B: Developmental and Reproductive Toxicology, Vol. 104, Issue 3
  • DOI: 10.1002/bdrb.21147

BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth
journal, June 1999

  • Schneider, Pascal; MacKay, Fabienne; Steiner, Véronique
  • The Journal of Experimental Medicine, Vol. 189, Issue 11
  • DOI: 10.1084/jem.189.11.1747

Baff and Rheumatic Autoimmune Disorders: Implications for Disease Management and Therapy
journal, January 2007

  • Bosello, S.; Pers, J. -O.; Rochas, C.
  • International Journal of Immunopathology and Pharmacology, Vol. 20, Issue 1
  • DOI: 10.1177/039463200702000101

Mice Transgenic for Baff Develop Lymphocytic Disorders along with Autoimmune Manifestations
journal, December 1999

  • Mackay, Fabienne; Woodcock, Stephen A.; Lawton, Pornsri
  • The Journal of Experimental Medicine, Vol. 190, Issue 11
  • DOI: 10.1084/jem.190.11.1697

Elevated serum BAFF levels in patients with systemic sclerosis: Enhanced BAFF signaling in systemic sclerosis B lymphocytes
journal, January 2005

  • Matsushita, Takashi; Hasegawa, Minoru; Yanaba, Koichi
  • Arthritis & Rheumatism, Vol. 54, Issue 1
  • DOI: 10.1002/art.21526

BLyS and APRIL in rheumatoid arthritis
journal, November 2005

  • Seyler, T. M.
  • Journal of Clinical Investigation, Vol. 115, Issue 11
  • DOI: 10.1172/JCI25265

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
journal, February 2011


Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus
journal, February 2014


Structure and signalling in the IL-17 receptor family
journal, July 2009

  • Gaffen, Sarah L.
  • Nature Reviews Immunology, Vol. 9, Issue 8
  • DOI: 10.1038/nri2586

Innate IL-17-producing cells: the sentinels of the immune system
journal, June 2010

  • Cua, Daniel J.; Tato, Cristina M.
  • Nature Reviews Immunology, Vol. 10, Issue 7
  • DOI: 10.1038/nri2800

Interleukin-17 and Type 17 Helper T Cells
journal, August 2009

  • Miossec, Pierre; Korn, Thomas; Kuchroo, Vijay K.
  • New England Journal of Medicine, Vol. 361, Issue 9
  • DOI: 10.1056/NEJMra0707449

The IL-23–IL-17 immune axis: from mechanisms to therapeutic testing
journal, August 2014

  • Gaffen, Sarah L.; Jain, Renu; Garg, Abhishek V.
  • Nature Reviews Immunology, Vol. 14, Issue 9
  • DOI: 10.1038/nri3707

Secukinumab: First Global Approval
journal, February 2015


Ixekizumab: First Global Approval
journal, April 2016


Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A
journal, April 2016

  • Liu, Ling; Kikly, Kristine; Lu, Jirong
  • Journal of Inflammation Research
  • DOI: 10.2147/JIR.S100940

Anti-interleukin-17 treatment of psoriasis
journal, December 2015


Brodalumab: First Global Approval
journal, August 2016


Local BAFF gene silencing suppresses Th17-cell generation and ameliorates autoimmune arthritis
journal, September 2008

  • Lai Kwan Lam, Q.; King Hung Ko, O.; Zheng, B. -J.
  • Proceedings of the National Academy of Sciences, Vol. 105, Issue 39
  • DOI: 10.1073/pnas.0806044105

B cell activating factor is central to bleomycin- and IL-17-mediated experimental pulmonary fibrosis
journal, January 2015


Association between IL-17 and IgA in the joints of patients with inflammatory arthropathies
journal, February 2017

  • Eliçabe, Ricardo Javier; Silva, Juan Eduardo; Dave, Mabel Noemí
  • BMC Immunology, Vol. 18, Issue 1
  • DOI: 10.1186/s12865-017-0189-9

B cell activating factor and T-helper 17 cells: possible synergistic culprits in the pathogenesis of Alopecia Areata
journal, January 2016

  • Elela, Mostafa A.; Gawdat, Heba I.; Hegazy, Rehab A.
  • Archives of Dermatological Research, Vol. 308, Issue 2
  • DOI: 10.1007/s00403-016-1617-z

Cytokine BAFF Released by Helicobacter pylori –Infected Macrophages Triggers the Th17 Response in Human Chronic Gastritis
journal, October 2014

  • Munari, Fabio; Fassan, Matteo; Capitani, Nagaja
  • The Journal of Immunology, Vol. 193, Issue 11
  • DOI: 10.4049/jimmunol.1302865

A pathogenic IFNα, BLyS and IL-17 axis in Systemic Lupus Erythematosus patients
journal, February 2016

  • López, Patricia; Rodríguez-Carrio, Javier; Caminal-Montero, Luis
  • Scientific Reports, Vol. 6, Issue 1
  • DOI: 10.1038/srep20651

Present and future of biologic drugs in primary Sjögren’s syndrome
journal, September 2016

  • Sambataro, Domenico; Sambataro, Gianluca; Dal Bosco, Ylenia
  • Expert Opinion on Biological Therapy, Vol. 17, Issue 1
  • DOI: 10.1080/14712598.2017.1235698

The making of bispecific antibodies
journal, December 2016


Alternative molecular formats and therapeutic applications for bispecific antibodies
journal, October 2015


Design and production of novel tetravalent bispecific antibodies
journal, February 1997

  • Coloma, M. Josefina; Morrison, Sherie L.
  • Nature Biotechnology, Vol. 15, Issue 2
  • DOI: 10.1038/nbt0297-159

A modular IgG-scFv bispecific antibody topology
journal, December 2009

  • Orcutt, Kelly Davis; Ackerman, Margaret E.; Cieslewicz, Maryelise
  • Protein Engineering, Design and Selection, Vol. 23, Issue 4
  • DOI: 10.1093/protein/gzp077

Ligand association rates to the inner-variable-domain of a dual-variable-domain immunoglobulin are significantly impacted by linker design
journal, September 2011


Discovery of Human Antibodies to Cell Surface Antigens by Capture Lift Screening of Phage-Expressed Antibody Libraries
journal, February 1998

  • Watkins, Jeffry D.; Beuerlein, Gregory; Wu, Herren
  • Analytical Biochemistry, Vol. 256, Issue 2
  • DOI: 10.1006/abio.1997.2523

Therapeutic Antibody Engineering To Improve Viscosity and Phase Separation Guided by Crystal Structure
journal, January 2016


The effect of charge mutations on the stability and aggregation of a human single chain Fv fragment
journal, June 2017

  • Austerberry, James I.; Dajani, Rana; Panova, Stanislava
  • European Journal of Pharmaceutics and Biopharmaceutics, Vol. 115
  • DOI: 10.1016/j.ejpb.2017.01.019

VH/VL interface engineering to promote selective expression and inhibit conformational isomerization of thrombopoietin receptor agonist single-chain diabody
journal, June 2010

  • Igawa, T.; Tsunoda, H.; Kikuchi, Y.
  • Protein Engineering Design and Selection, Vol. 23, Issue 8
  • DOI: 10.1093/protein/gzq034

The role of interface framework residues in determining antibody VH/VL interaction strength and antigen-binding affinity
journal, May 2006


Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions
journal, May 1994

  • Reiter, Yoram; Brinkmann, Ulrich; Kreitman, Robert J.
  • Biochemistry, Vol. 33, Issue 18
  • DOI: 10.1021/bi00184a014

Engineering antibody Fv fragments for cancer detection and therapy: Bisulfide-stabilized Fv fragments
journal, October 1996

  • Reiter, Yoram; Brinkmann, Ulrich; Lee, Byungkook
  • Nature Biotechnology, Vol. 14, Issue 10
  • DOI: 10.1038/nbt1096-1239

Towards a universal disulphide stabilised single chain Fv format: importance of interchain disulphide bond location and vL-vH orientation
journal, May 2012

  • Weatherill, E. E.; Cain, K. L.; Heywood, S. P.
  • Protein Engineering Design and Selection, Vol. 25, Issue 7
  • DOI: 10.1093/protein/gzs021

A recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
journal, August 1993

  • Brinkmann, U.; Reiter, Y.; Jung, S. H.
  • Proceedings of the National Academy of Sciences, Vol. 90, Issue 16
  • DOI: 10.1073/pnas.90.16.7538

Extrinsic Fluorescent Dyes as Tools for Protein Characterization
journal, January 2008


Pharmacokinetics and safety of single doses of tabalumab in subjects with rheumatoid arthritis or systemic lupus erythematosus: PK and safety of i.v. and s.c. tabalumab in subjects with SLE or RA
journal, February 2016

  • Witcher, Jennifer; Fleischmann, Roy; Chindalore, Vishala L.
  • British Journal of Clinical Pharmacology, Vol. 81, Issue 5
  • DOI: 10.1111/bcp.12860

Biophysical Properties of Human Antibody Variable Domains
journal, January 2003


Domain Interactions in the Fab Fragment: A Comparative Evaluation of the Single-chain Fv and Fab Format Engineered with Variable Domains of Different Stability
journal, April 2005

  • Röthlisberger, Daniela; Honegger, Annemarie; Plückthun, Andreas
  • Journal of Molecular Biology, Vol. 347, Issue 4
  • DOI: 10.1016/j.jmb.2005.01.053

Conserved amino acid networks involved in antibody variable domain interactions
journal, July 2009

  • Wang, Norman; Smith, William F.; Miller, Brian R.
  • Proteins: Structure, Function, and Bioinformatics, Vol. 76, Issue 1
  • DOI: 10.1002/prot.22319

Prediction of VH-VL domain orientation for antibody variable domain modeling: Prediction of VH-VL domain orientation
journal, February 2015

  • Bujotzek, Alexander; Dunbar, James; Lipsmeier, Florian
  • Proteins: Structure, Function, and Bioinformatics, Vol. 83, Issue 4
  • DOI: 10.1002/prot.24756

Determinants of the assembly and function of antibody variable domains
journal, September 2017


Study of the ?molten globule? intermediate state in protein folding by a hydrophobic fluorescent probe
journal, January 1991

  • Semisotnov, G. V.; Rodionova, N. A.; Razgulyaev, O. I.
  • Biopolymers, Vol. 31, Issue 1
  • DOI: 10.1002/bip.360310111

Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv
journal, January 1994

  • Reiter, Yoram; Brinkmann, Ulrich; Webber, Keith O.
  • "Protein Engineering, Design and Selection", Vol. 7, Issue 5
  • DOI: 10.1093/protein/7.5.697

A broad range of Fab stabilities within a host of therapeutic IgGs
journal, April 2007

  • Garber, Ellen; Demarest, Stephen J.
  • Biochemical and Biophysical Research Communications, Vol. 355, Issue 3
  • DOI: 10.1016/j.bbrc.2007.02.042

Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo
journal, July 2009

  • Labrijn, Aran F.; Buijsse, Antonio Ortiz; van den Bremer, Ewald T. J.
  • Nature Biotechnology, Vol. 27, Issue 8
  • DOI: 10.1038/nbt.1553

Rapid and efficient site-specific mutagenesis without phenotypic selection.
journal, January 1985

  • Kunkel, T. A.
  • Proceedings of the National Academy of Sciences, Vol. 82, Issue 2, p. 488-492
  • DOI: 10.1073/pnas.82.2.488

Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda
journal, December 1989


Phaser crystallographic software
journal, July 2007

  • McCoy, Airlie J.; Grosse-Kunstleve, Ralf W.; Adams, Paul D.
  • Journal of Applied Crystallography, Vol. 40, Issue 4
  • DOI: 10.1107/S0021889807021206

Overview of the CCP 4 suite and current developments
journal, March 2011

  • Winn, Martyn D.; Ballard, Charles C.; Cowtan, Kevin D.
  • Acta Crystallographica Section D Biological Crystallography, Vol. 67, Issue 4
  • DOI: 10.1107/S0907444910045749